Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates
July 30 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will host
a conference call and webcast on Friday, August 6, 2021 at 8:00
a.m. ET to report financial results for the second quarter ended
June 30, 2021 and provide business updates.
To access the call, please dial 877-303-9226
(domestic) or 409-981-0870 (international) and provide the
Conference ID 3876353. A live webcast of the presentation will be
available on the Investors & Media section of the Mersana
website at www.mersana.com.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (UpRi), is a
Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a
single-arm registration strategy, in patients with
platinum-resistant ovarian cancer as well as in the expansion
portion of a Phase 1 proof-of-concept clinical study in patients
with NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product
candidate targeting NaPi2b-expressing tumors, was created using
Mersana’s customizable and homogeneous Dolasynthen platform and is
in the dose escalation portion of a Phase 1 proof-of-concept
clinical study. The Company’s early-stage programs include
XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a
STING-agonist ADC developed using the Company’s Immunosynthen
platform. In addition, multiple partners are using Mersana’s
Dolaflexin platform to advance their ADC pipelines.
Contact:
Investor & Media ContactSarah Carmody,
617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024